Table 3.

Changes over 12 Months in Immune Activation and Exhaustion Markers

Median (quartile 1, quartile 3)	All Subjects (N=51)	P∘	Standard Dose (N=21)	P∘	Moderate Dose (N=18)	P∘	High Dose (N=12)	P∘	Moderate+High Dose (N=30)	P∘	P*	P**	P***
% CD4+CD38+HLA-DR+a, b	−0.2 (−0.7, +0.1)	0.005	−0.1 (−0.6, +0.2)	0.31	−0.2 (−0.8, +0.03)	0.07	−0.4 (−0.9, −0.1)	0.04	−0.3 (−0.8, −0.1)	0.002	0.35	0.20	0.20
% CD8+CD38+HLA-DR+a	−0.7 (−1.9, +0.2)	0.003	−0.1 (−1.6, +0.4)	0.30	−1.0 (−2.6, +0.2)	0.55	−1.0 (−2.8, −0.1)	0.03	−1.0 (−2.7, 0.0)	0.004	0.54	0.76	0.33
% CD4+CD38+HLA-DR+PD1+a,b	−0.2 (−0.4, +0.03)	0.001	−0.2 (−0.4, +0.1)	0.10	−0.06 (−0.3, −0.02)	0.37	−0.3 (−0.4, +0.001)	0.09	−0.2 (−0.3, −0.02)	0.004	0.98	0.27	0.77
% CD8+CD38+HLA-DR+PD1+a	−0.2 (−0.7, +0.2)	0.12	−0.02 (−0.7, +0.3)	0.74	−0.2 (−0.7, +0.2)	1.00	−0.3 (−0.6, −0.01)	0.18	−0.3 (−0.7, +0.1)	0.08	0.68	0.54	0.45
% CD14+CD16+a,c	−2.7 (−10.4, +2.6)	0.03	−3.2 (12.2, +5.1)	0.25	0.5 (−2.9, +4.5)	0.70	−8.9 (−18.0, +2.3)	0.004	−2.5 (−10.4, +15)	0.04	0.27	0.36	0.86
% CD14dimCD16+a,c	−2.6 (−5.8, +4.9)	0.32	−0.2 (−9.3, +7.3)	0.70	−1.9 (−4.3, +3.3)	0.43	−3.5 (−5.7, +3.8)	0.46	−3.3 (−5.7, +3.5)	0.25	0.99	0.26	0.83

N.B. P-values with bolded font designate those <0.05;

^∘P value within group;

^*P value between standard vs. moderate groups;

^**P value between standard vs. high groups;

^***P value between standard vs. moderate+high groups;

^†Standard dose = 18,000 IU given monthly for 12 months (equivalent to 600 IU/daily);

^‡Moderate dose = 60,000 IU given monthly for 12 months (equivalent to 2,000 IU/daily);

^¥High dose = 120,000 IU given monthly for 12 months (equivalent to 4,000 IU/daily).

^aData represent the % of that cell type expressing the given phenotype;

^b1 subject with no data due to cell viability issues;

^c3 subjects with no data due to cell viability issues